eculizumab
alexion pharmaceuticals
['eculizumab', 'in person']
#ash22 de latour: breakthrough hemolysis 2/62 with iptacoban vs 6/35 with mab therapy. no serious infection aes with iptacoban and no discontinuations for toxicity. cool advance for a rare disease (and undoubtedly cheaper than eculizumab!). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)